I’ve been busy, so missed out on Keith’s blogposts on the subject of Codon shutting down it’s doors. It’s a sign of the times. Very difficult to be a company looking for financing these days, but I wonder if it has anything to say about the maturity of synthetic biology as a commercial enterprise.
Codon’s core technology was a platform for designing and optimizing proteins and pathways for a variety of applications. I am not quite sure what their core target market was. I suspect energy was a big one.
That they look like they’ve gone under would suggest there are not enough people out there looking for the kinds of products Codon offered. I don’t know if they were planning to take any forward themselves, or license them out. They have a good IP position, which should have some value.
Hopefully we’ll learn more in coming weeks and good luck to everyone who used to work there.
A synthetic biology company bites the dust
I’ve been busy, so missed out on Keith’s blog posts on the subject of Codon shutting down it’s doors. It’s a sign of the times. Very difficult to be a company looking for financing these days, but I wonder if it has anything to say about the maturity of synthetic biology as a commercial enterprise.
Codon’s core technology was a platform for designing and optimizing proteins and pathways for a variety of applications. I am not quite sure what their core target market was. I suspect energy was a big one.
That they look like they’ve gone under would suggest there are not enough people out there looking for the kinds of products Codon offered. I don’t know if they were planning to take any forward themselves, or license them out. They have a good IP position, which should have some value.
Hopefully we’ll learn more in coming weeks and good luck to everyone who used to work there.
Related articles by Zemanta